 Connection
Kristine Erlandson to Weight Gain
This is a "connection" page, showing publications Kristine Erlandson has written about Weight Gain.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
2.153 |
|
|
|
-
Kousari AE, Wilson MP, Hawkins KL, Bandali MM, Henao-MartÃnez AF, Gardner EM, Erlandson KM. Weight change with antiretroviral switch from integrase inhibitor or tenofovir alafenamide-based to Doravirine-Based regimens in people with HIV. HIV Res Clin Pract. 2024 12; 25(1):2339576.
Score: 0.636
-
Guaraldi G, Milic J, Bacchi E, Carli F, Menozzi M, Franconi I, Raimondi A, Ciusa G, Masi V, Belli M, Guaraldi S, Aprile E, Mancini M, Mussini C, Lake JE, Erlandson KM. Contribution of integrase inhibitor use, body mass index, physical activity and caloric intake to weight gain in people living with HIV. HIV Res Clin Pract. 2022 11 22; 24(1):1-6.
Score: 0.572
-
Erlandson KM, Kitch DW, Kantor A, Belaunzaran-Zamudio PF, Brown TT, Fichtenbaum CJ, Heath SL, Sattler FR, Lake JE. The Bounce-back Effect: What Happens After Cessation of Low-dose Semaglutide in People With HIV. Clin Infect Dis. 2026 Mar 17; 82(3):e544-e548.
Score: 0.180
-
Bares SH, Wu X, Tassiopoulos K, Lake JE, Koletar SL, Kalayjian R, Erlandson KM. Weight Gain After Antiretroviral Therapy Initiation and Subsequent Risk of Metabolic and Cardiovascular Disease. Clin Infect Dis. 2024 02 17; 78(2):395-401.
Score: 0.156
-
Erlandson KM, Mohaweche R, Morrow M, Mawhinney S, Khuu V, Boyd M, Balasubramanyam A, Melanson EL, Lake JE. Energy balance and body composition after switch between integrase strand transfer inhibitors and doravirine among people with HIV. J Antimicrob Chemother. 2024 01 03; 79(1):179-185.
Score: 0.154
-
Erlandson KM, Wu K, Lake JE, Samuels DC, Bares SH, Tassiopoulos K, Koethe JR, Brown TT, Leonard M, Benson CA, Haas DW, Hulgan T. Mitochondrial DNA haplogroups and weight gain following switch to integrase strand transfer inhibitor-based antiretroviral therapy. AIDS. 2021 03 01; 35(3):439-445.
Score: 0.127
-
Lake JE, Wu K, Bares SH, Debroy P, Godfrey C, Koethe JR, McComsey GA, Palella FJ, Tassiopoulos K, Erlandson KM. Risk Factors for Weight Gain Following Switch to Integrase Inhibitor-Based Antiretroviral Therapy. Clin Infect Dis. 2020 12 03; 71(9):e471-e477.
Score: 0.125
-
Mave V, Erlandson KM, Gupte N, Balagopal A, Asmuth DM, Campbell TB, Smeaton L, Kumarasamy N, Hakim J, Santos B, Riviere C, Hosseinipour MC, Sugandhavesa P, Infante R, Pillay S, Cardoso SW, Tripathy S, Mwelase N, Berendes S, Andrade BB, Thomas DL, Bollinger RC, Gupta A. Inflammation and Change in Body Weight With Antiretroviral Therapy Initiation in a Multinational Cohort of HIV-Infected Adults. J Infect Dis. 2016 Jul 01; 214(1):65-72.
Score: 0.090
-
Koethe JR, Lake JE, Kantor A, Smeaton L, Erlandson K, Moran L, Belaunzaran-Zamudio P, Landay A, Campo RE, Debroy P, Bennet JA, O'Halloran J, Han WM, Alli O, Leonard M, Gulick RM. A 48-Week, Randomized Controlled Trial of Doravirine for Individuals With HIV and Obesity on Integrase Inhibitors and Tenofovir Alafenamide: The Do IT Study (ACTG A5391). Clin Infect Dis. 2026 Jul 23; 83(1):e81-e89.
Score: 0.046
-
Wu K, Koethe J, Hulgan T, Brown T, Bares SH, Tassiopoulos K, Lake JE, Leonard M, Samuels DC, Erlandson K, Haas DW. Pharmacogenetics of weight gain following switch from efavirenz- to integrase inhibitor-containing regimens. Pharmacogenet Genomics. 2024 02 01; 34(2):25-32.
Score: 0.038
-
Sax PE, Erlandson KM, Lake JE, Mccomsey GA, Orkin C, Esser S, Brown TT, Rockstroh JK, Wei X, Carter CC, Zhong L, Brainard DM, Melbourne K, Das M, Stellbrink HJ, Post FA, Waters L, Koethe JR. Weight Gain Following Initiation of Antiretroviral Therapy: Risk Factors in Randomized Comparative Clinical Trials. Clin Infect Dis. 2020 09 12; 71(6):1379-1389.
Score: 0.031
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|